The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous ...
Recursion Pharmaceuticals Inc. stocks have been trading down by -4.08 percent after cautious reaction to its latest AI ...
Cathie Wood’s ARK Invest continued to reshuffle its healthcare portfolio Monday across its ETFs, selling heavily in Twist ...
Cathie Wood's ARK Invest executed a $22 million healthcare portfolio rotation on Monday, selling approximately $18 million of ...
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
ARK Invest sold Twist Bioscience shares and bought Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte stock on ...
Investor's Business Daily on MSN
Stock market today: Dow, S&P 500 rally; Cathie Wood buys this stock amid 56% dive
The Dow Jones index rises on the stock market today as Treasury yields fall. AMD, Nvidia and Tesla rally. An AI stock tests ...
ARK Invest sold $17.1M in Twist Bioscience shares and purchased Recursion Pharmaceuticals, Intellia Therapeutics, and ...
Pune, India, October 6th, 2026, FinanceWireThis is a paid advertisement.Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ...
Tempus AI slides 7.63% today to $77.22 as selling pressure emerges despite bullish momentum and FDA clearance news.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom and Fate Therapeutics . Dexcom (DXCM) Citi analyst Joanne Wuensch maintained a Buy rating ...
A new Green's-function method models pyramidal horn antennas near layered reflecting surfaces nearly three times faster than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results